Skip to main content
. 2018 Sep 27;13(9):e0204870. doi: 10.1371/journal.pone.0204870

Table 1. Clinical characteristics of patients in the treated and the untreated group.

Untreated group, n (%) Treated group, n (%)
All patients 11 (100) 30 (100)
Age*
≥45 years 5 (45) 11 (37)
<45 years 6 (55) 19 (63)
Sex
Male 8 (73) 18 (60)
Female 3 (27) 12 (40)
Histologic subtype
Nodular sclerosis 6 (55) 22 (73)
Mixed cellularity 5 (45) 8 (27)
Stage**
IA-IIA 5 (45) 11 (37)
IIB-IVB 6 (55) 17 (57)
Missing 0 (0) 2 (6)
Primary treatment received
Radiotherapy only § 3 (10)
2–4 ABVD or MOPP/A(B)VD + RT § 5 (17)
6–8 ABVD or MOPP/A(B)VD ± RT § 10 (33)
6–8 BEACOPP § 3 (10)
Other*** § 7 (23)
Missing § 2 (7)
Autologous stem cell transplantation at relapse
Yes § 14
No § 12
Missing § 4

*Age at diagnosis of relapse in the treated group, and age at primary diagnosis in the untreated group.

**Stage at primary diagnosis.

***Other chemotherapy regimens were: OEPA (3 children and 1 elderly), one patient each received VACOP-B, Bendamustine and CHOP.

§Not applicable.

ABVD = Doxorubicine, Bleomycin, Vinblastine, Dacarbazine, BEACOPP = Bleomycin, Etoposide, Doxorubicine, Cyclophosphamide, Vincristine, Procarbazine, Prednisolone, CHOP = Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone, MOPP = Mustargen, Oncovin, Procarbazine, Prednisolone, OEPA = Oncovin, Etoposide, Prednisolone, Doxorubicine, VACOP-B = Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisolone, Bleomycin